Results 191 to 199 of about 18,010 (199)

Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens

Antimicrobial Agents and Chemotherapy, 2020
Eric Wenzler
exaly  

Cloxacillin/meropenem/vaborbactam

Reactions Weekly
openaire   +1 more source

Is meropenem–vaborbactam as effective as usual antibiotics in patients with serious infections?

Evidence-Based Practice, 2019
Joy C. Anyanwu, Edward Foley
openaire   +1 more source

Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model

Antimicrobial Agents and Chemotherapy, 2018
Olga Lomovskaya, Mojgan Sabet
exaly  

In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China

Journal of Antimicrobial Chemotherapy, 2018
Qiwen Yang, Olga Lomovskaya, Ge Zhang
exaly  

In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance

Diagnostic Microbiology and Infectious Disease, 2019
Erin McCreary, Barry C Fox
exaly  

Pharmacokinetics of the Meropenem Component of Meropenem‐Vaborbactam in the Treatment of KPC‐Producing Klebsiella pneumoniae Bloodstream Infection in a Pediatric Patient

Pharmacotherapy, 2018

exaly  

P241 Safety and efficacy of meropenem-vaborbactam in people with cystic fibrosis (pwCF)

Journal of Cystic Fibrosis
M. Abdalaziz, H. Saumtally, G. Spoletini, E. Williams, C. Etherington, I. Clifton, M. Denton, D. Peckham   +7 more
openaire   +1 more source

Meropenem/vaborbactam (Vabomere) for complicated urinary tract infection.

The Medical letter on drugs and therapeutics, 2018
openaire   +1 more source